Edwards Lifesciences Corp (EW) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Edwards Lifesciences Corp stock $81.94, price $101, that is 18.7% below the price, quality 67 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $59.70 – $130.68 · fair‑value band $61.46 – $102.64 · the $100.82 price screens above the $81.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Edwards Lifesciences in your weekly email
Every Wednesday you see whether Edwards Lifesciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Show moreShow less
It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Stock analysis
Edwards Lifesciences Corp (EW) currently trades at $100.82, while our model-based Fair Value estimate is $81.94, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $50.75 per share, and 0 of the 24 models we run sit above the $100.82 price.
Bear case: the Economic Profit group reads lowest at $17.98, and 24 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $61.46 (bear) to $102.64 (bull), the price of $100.82 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Edwards Lifesciences Corp reported revenue of $6.1B in FY2025 versus $5.2B in FY2021, a compound +3.8%/yr. Reported net income was $1.1B in FY2025, compounding −8.1%/yr from FY2021.
Key figures
Market cap $58.2B Large · P/E ratio 60.0 · P/S ratio 8.94 · EPS (TTM) $1.68 · Net margin 15.4% · Return on equity 9.2% · Return on assets (EBIT) 15.7% · Operating margin 29.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 74 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades at its 52-week high and 33% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −19%, EW screens richer than that median.
Fair Value models
Bear$61.46Fair Value $81.94Bull$102.64
Price $100.82 · Downside -18.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.43 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 7 officers or directors sold shares worth $11.3M and none bought.
SaleDaniel J. LippisCVP, TAVR12× since Nov 10, 2025: 10,849 shares, avg. $85.23$924,636Oct 8, 202610b5-1 plan
SaleAndrew M. DahlSVP, Corporate Controller2× since May 29, 2026: 1,112 shares, avg. $88.52$98,390Aug 31, 2026
SaleAnnette BrulsCVP, EMEACLA2,644 shares at $89.98$237,907Aug 28, 2026
SaleWayne MarkowitzCVP, JAPAC5× since Dec 8, 2025: 12,190 shares, avg. $85.51$1.0MAug 26, 2026
SaleDaveen ChopraCVP, TMTT, Surgical & IHFM3× since Dec 11, 2025: 35,300 shares, avg. $90.37$3.2MAug 26, 2026
SaleBernard J ZovighianCEO, Director5× since Dec 8, 2025: 87,575 shares, avg. $79.90$7.0MJul 27, 2026
SaleDonald E Bobo JrCVP,Strategy/Corp Development8× since Dec 10, 2025: 133,199 shares, avg. $83.73$11.2MMay 27, 2026
SaleScott B. UllemCVP, Chief Financial Officer4× since Nov 10, 2025: 46,700 shares, avg. $82.98$3.9MApr 9, 202610b5-1 plan
SaleHeisz Leslie StoneDirector2,615 shares at $83.41$218,117Dec 12, 2025
Plus 36 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.78/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Start year 2020 (pandemic). Over 10 years: +9.3% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+2.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2.2% vs 7.7%, slowing
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 25%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +17.8% a year for the price and +6.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Edwards shows pricing power and efficiency through high gross margins and cash conversion, yet moderate ROE together with absent data in several categories limits a fuller view of business quality.
Main risk: Medtronic with its Evolut platform and Abbott with MitraClip and other devices could capture more structural heart procedures from Edwards and force price concessions on transcatheter valves.
Bull case: Edwards could leverage its new pediatric AUTUS valve and AI-enabled procedural tools developed with partners to defend share against rivals and accelerate organic expansion into underserved segments.
Bear case: Sustained share losses to Medtronic and Abbott combined with blocked acquisitions and patent setbacks could confine Edwards to a narrower position in a maturing structural heart market with slower growth.
Edwards has gained FDA approval for the AUTUS valve, its first surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease that can be expanded as the child grows via a minimally invasive procedure. This uses polymeric leaflets and aims to reduce repeated open-heart surgeries, extending the company's structural heart expertise into a younger patient group. Does this pediatric step open a sizable new growth avenue for Edwards, or does it stay a narrow addition to the established business?
Compare Edwards Lifesciences Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 322 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−18.7% · Above median
Profitability
Return on equity (12 months)9.2% · Above median
Return on assets7.8% · Top 25%
Net margin (12 months)15.4% · Top 25%
Operating margin (12 months)29.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)13.6% · Above median
Balance sheet
Debt / equity0.06× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Edwards Lifesciences Corp (EW) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $81.94 versus a price of $100.82, about 19% lower (overvalued).
What is the fair value of EW?
Our model-based fair value for Edwards Lifesciences Corp is $81.94 (as of Nov 5, 2026), built from audited fundamentals. The current price: $100.82.
What is the quality score of EW?
Edwards Lifesciences Corp has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Edwards Lifesciences Corp (EW)?
Our model-based price target is the fair value of $81.94 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $61.46, optimistic scenario $102.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Edwards Lifesciences Corp stock forecast for 2026?
Our models put fair value at $81.94, about 19% lower versus a price of $100.82 (overvalued). Cautious scenario $61.46, optimistic scenario $102.64. The calculation is refreshed regularly with new filings.
What is the revenue of Edwards Lifesciences Corp (EW)?
Edwards Lifesciences Corp reported trailing-twelve-month revenue of about $6.5B (latest available figure, as of Nov 5, 2026).
What growth is priced into Edwards Lifesciences Corp (EW)?
For today's price to be fair in a discounted-cash-flow model, Edwards Lifesciences Corp would have to grow free cash flow by +20.6 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.7 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of EW use?
Our models discount Edwards Lifesciences Corp at 8.8 %: a base by market capitalisation (large), damped by beta 0.83, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Edwards Lifesciences Corp that is +20.6 % per year a year over ten years, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has Edwards Lifesciences Corp (EW) delivered so far?
Over the past 5 years revenue at Edwards Lifesciences Corp grew +6.7 % a year. The price currently implies +20.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Edwards Lifesciences Corp (EW) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Edwards Lifesciences Corp (+20.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Edwards Lifesciences Corp (EW)?
The free-cash-flow yield on the price is 2.29 %: that much free cash flow Edwards Lifesciences Corp produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Edwards Lifesciences Corp (EW)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Edwards Lifesciences Corp it is $81.94 per share (as of Nov 5, 2026), against a price of $100.82. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Edwards Lifesciences Corp stock overvalued or undervalued in 2026?
As of Nov 5, 2026, EW trades above its calculated fair value: price $100.82, fair value $81.94, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EW?
No. The price is what the market pays today ($100.82); the fair value is what the company's own numbers justify ($81.94). For Edwards Lifesciences Corp the two are $18.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is Edwards Lifesciences Corp worth?
The market values Edwards Lifesciences Corp at about $58.2B (market capitalisation, as of Nov 5, 2026). Per share that is $100.82; our models calculate a fair value of $81.94 per share.
What do the bullish and bearish scenarios say about EW?
Our models span a range for Edwards Lifesciences Corp: cautious scenario $61.46, base $81.94, optimistic $102.64 per share (as of Nov 5, 2026, price $100.82). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EW?
Edwards Lifesciences Corp trades at a price-to-earnings ratio of 60.0 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $81.94 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 39.4 (reported for FY2025: 54.6). Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings, FY2025 ex one-offs: 33.2. Other multiples: PEG 2.0, P/B 5.6, P/S 8.9, EV/EBITDA 28.0.
What is the PEG ratio of EW?
The PEG ratio of Edwards Lifesciences Corp is 1.99 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Edwards Lifesciences Corp (EW)?
Balance-sheet figures for Edwards Lifesciences Corp (as of Nov 5, 2026): return on equity 9.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is EW from its 52-week high?
Edwards Lifesciences Corp trades at $100.82, at its 52-week high of $100.82 and 33% above the low of $75.87 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $81.94 is for.
Which stocks are comparable to Edwards Lifesciences Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Edwards Lifesciences Corp stock attractive at the current price?
The data as of Nov 5, 2026: price $100.82, calculated fair value $81.94 (−19%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EW calculated?
We run Edwards Lifesciences Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $81.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Edwards Lifesciences Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Edwards Lifesciences Corp (EW)?
The closing price on Nov 5, 2026 was $100.82. Our model-based fair value is $81.94, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Edwards Lifesciences Corp right now?
Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Edwards Lifesciences Corp (EW) come from?
Earnings per share at Edwards Lifesciences Corp grew +16.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +10.5 %, EBIT margin +0.8 %, tax rate +2.3 %, residual (interest, one-offs) +2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Edwards Lifesciences Corp
How large is the market capitalisation of Edwards Lifesciences Corp (EW)?
The market capitalisation of Edwards Lifesciences Corp is $58.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Edwards Lifesciences Corp (EW)?
The price-to-sales ratio of Edwards Lifesciences Corp is 8.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Edwards Lifesciences Corp (EW)?
Earnings per share at Edwards Lifesciences Corp are $1.68 (price ÷ EPS = P/E 60.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Edwards Lifesciences Corp (EW)?
The net margin of Edwards Lifesciences Corp is 15.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Edwards Lifesciences Corp (EW)?
The return on equity (ROE) of Edwards Lifesciences Corp is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Edwards Lifesciences Corp (EW)?
On an EBIT basis the return on assets of Edwards Lifesciences Corp is 15.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Edwards Lifesciences Corp (EW)?
The operating margin of Edwards Lifesciences Corp is 29.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Edwards Lifesciences Corp (EW)?
Revenue at Edwards Lifesciences Corp is growing +13.6% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Edwards Lifesciences Corp (EW)?
Earnings per share at Edwards Lifesciences Corp are growing −25.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Edwards Lifesciences Corp (EW) hold?
Edwards Lifesciences Corp holds more cash than debt, $2.2B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Edwards Lifesciences Corp in the live analysis
One click puts Edwards Lifesciences Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026